drugset
drugset / Trial / NCT07182149

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

NCT07182149 ↗

Phase 1 Recruiting 150 enrolled Normunity AccelCo, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

Timeline

Start
2025-10-30
Primary completion
2027-05-30
Completion
2028-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject NRM-823 Unknown — —

Indications

cervical cancer endometrial cancer esophageal adenocarcinoma esophageal squamous cell carcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian cancer triple-negative breast carcinoma